Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Snapshot

Systemic therapy in advanced hepatocellular carcinoma

Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):516-519. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0051

View: 941 Download: 92 Citations: 3

Correspondence

Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):513-515. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2023.0044

View: 624 Download: 26

Letter to the Editor

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 699 Download: 37

Original Article

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea

Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong

Clin Mol Hepatol. 2023;29(2):496-509. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0345

View: 951 Download: 77

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase

Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):482-495. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0322

View: 1279 Download: 108 Citations: 4

Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions

Jing Yang, Xujiao Tang, Zhu Liang, Mingzhu Chen, Lixin Sun

Clin Mol Hepatol. 2023;29(2):465-481. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0327

View: 1066 Download: 100 Citation: 1

Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma

Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):453-464. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0450

View: 1174 Download: 80

Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study

Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith

Clin Mol Hepatol. 2023;29(2):433-452. Published online January 4, 2023

DOI: https://doi.org/10.3350/cmh.2022.0316

View: 1684 Download: 139 Citations: 4

Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease

Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi

Clin Mol Hepatol. 2023;29(2):417-432. Published online November 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0205

View: 1723 Download: 97 Citation: 1

Editorial

The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Young-Joo Jin

Clin Mol Hepatol. 2023;29(2):414-416. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0055

View: 2432 Download: 48

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease

Byeong Geun Song, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):411-413. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0058

View: 632 Download: 24

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease

Ji-Won Park, Ki Tae Suk

Clin Mol Hepatol. 2023;29(2):408-410. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0085

View: 639 Download: 39

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 765 Download: 32

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 682 Download: 29

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer, Mohamed Naffaa, Nimer Assy

Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0045

View: 754 Download: 68

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 707 Download: 39

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed

Philipp Kasper, Münevver Demir, Hans-Michael Steffen

Clin Mol Hepatol. 2023;29(2):390-393. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0059

View: 647 Download: 22

Implications of comorbidities in nonalcoholic fatty liver disease

Sherlot Juan Song, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0066

View: 802 Download: 45

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 686 Download: 35

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 662 Download: 40

The growing burden of non-alcoholic fatty liver disease on mortality

Ju-Yeon Cho, Won Sohn

Clin Mol Hepatol. 2023;29(2):374-376. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0084

View: 625 Download: 30

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0086

View: 725 Download: 43

Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?

Joo Hyun Oh, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):367-370. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0054

View: 631 Download: 35

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 659 Download: 43

The current trends in the health burden of primary liver cancer across the globe

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(2):358-362. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0092

View: 757 Download: 30

The latest global burden of liver cancer: A past and present threat

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):355-357. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0070

View: 667 Download: 27

Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan

San-Chi Chen

Clin Mol Hepatol. 2023;29(2):352-354. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0101

View: 718 Download: 34

Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap

Shen-Yung Wang

Clin Mol Hepatol. 2023;29(2):349-351. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0082

View: 746 Download: 28

The prime time for management of hepatocellular carcinoma in Hong Kong

Landon L. Chan, Stephen L. Chan

Clin Mol Hepatol. 2023;29(2):345-348. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0094

View: 681 Download: 29

Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences

Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen

Clin Mol Hepatol. 2023;29(2):342-344. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0106

View: 744 Download: 32

Viewed By 4109	Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease
Viewed By 2677	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Viewed By 2432	The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Viewed By 2405	Recent updates on the management of autoimmune hepatitis
Viewed By 2401	Management of refractory ascites

Cited By 99	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Cited By 42	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
Cited By 42	From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Cited By 40	Obesity and the risk of primary liver cancer: A systematic review and meta-analysis
Cited By 38	The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Topics